2 Information about empagliflozin
Marketing authorisation indication
2.1 Empagliflozin (Jardiance, Boehringer Ingelheim) is indicated in adults for 'the treatment of symptomatic chronic heart failure'.
2.2 Empagliflozin is recommended for treating heart failure with reduced ejection fraction in adults (NICE technology appraisal guidance 773).
Dosage in the marketing authorisation
2.3 The dosage schedule is available in the summary of product characteristics for empagliflozin.